Eversept Partners, LP - Q4 2021 holdings

$1.57 Billion is the total value of Eversept Partners, LP's 107 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .

 Value Shares↓ Weighting
QQQ NewINVESCO QQQ TRput$114,023,810286,600
+100.0%
7.28%
BHVN NewBIOHAVEN PHARMACTL HLDG CO L$43,427,927315,129
+100.0%
2.77%
IWM NewISHARES TRput$27,806,250125,000
+100.0%
1.78%
IWO NewISHARES TRput$26,374,50090,000
+100.0%
1.68%
CLDX NewCELLDEX THERAPEUTICS INC NEW$22,893,350592,478
+100.0%
1.46%
ARKG NewARK ETF TRcall$14,930,312243,800
+100.0%
0.95%
XBI NewSPDR SER TRcall$12,741,048113,800
+100.0%
0.81%
SYNH NewSYNEOS HEALTH INCcl a$8,790,64085,612
+100.0%
0.56%
PODD NewINSULET CORP$8,027,86430,172
+100.0%
0.51%
BIIB NewBIOGEN INC$7,927,19733,041
+100.0%
0.51%
CERN NewCERNER CORP$7,221,69277,543
+100.0%
0.46%
XENE NewXENON PHARMACEUTICALS INC$6,545,374209,519
+100.0%
0.42%
NVRO NewNEVRO CORP$5,356,61966,074
+100.0%
0.34%
ZNTL NewZENTALIS PHARMACEUTICALS INC$5,309,48263,163
+100.0%
0.34%
MRK NewMERCK & CO INC$5,025,10719,456
+100.0%
0.32%
AUPH NewAURINIA PHARMACEUTICALS INC$4,605,652201,384
+100.0%
0.29%
CVAC NewCUREVAC N V$2,916,93385,017
+100.0%
0.19%
PGNY NewPROGYNY INCput$2,517,50050,000
+100.0%
0.16%
GRTS NewGRITSTONE BIO INC$2,187,808170,125
+100.0%
0.14%
ACAD NewACADIA PHARMACEUTICALS INCcall$1,974,56484,600
+100.0%
0.13%
ESTA NewESTABLISHMENT LABS HLDGS INC$1,699,01025,137
+100.0%
0.11%
UTHR NewUNITED THERAPEUTICS CORP DELcall$1,642,2087,600
+100.0%
0.10%
VCRA NewVOCERA COMMUNICATIONS INC$970,65514,970
+100.0%
0.06%
MRUS NewMERUS N V$604,20019,000
+100.0%
0.04%
CSU NewSONIDA SENIOR LIVING INC$433,30415,209
+100.0%
0.03%
BKD NewBROOKDALE SR LIVING INC$408,39379,146
+100.0%
0.03%
JYNT NewJOINT CORPput$361,2955,500
+100.0%
0.02%
MNKD NewMANNKIND CORPcall$218,50050,000
+100.0%
0.01%
GLYC NewGLYCOMIMETICS INC$144,000100,000
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2023-11-08
  • View 13F-HR/A filed 2023-11-08
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMARIN CORP PLC21Q3 202312.5%
DANAHER CORPORATION21Q3 20238.1%
AFFIMED N V20Q3 20230.9%
ARGENX SE19Q3 20232.0%
GSK PLC18Q2 202213.1%
ASCENDIS PHARMA A/S18Q1 20227.7%
SANOFI18Q4 20227.2%
ENSIGN GROUP INC18Q1 20228.6%
CENTENE CORP DEL18Q3 20231.5%
ZOGENIX INC17Q4 202112.4%

View Eversept Partners, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Eversept Partners, LP Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cabaletta Bio, Inc.February 14, 2023282,8741.0%
Teligent, Inc.Sold outFebruary 16, 202100.0%
Teligent, Inc.February 14, 20204,501,7998.4%

View Eversept Partners, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
13F-HR/A2023-11-08
13F-HR/A2023-11-08
13F-HR/A2023-11-08
13F-HR/A2023-11-08
13F-HR/A2023-11-08
13F-HR/A2023-11-08
13F-HR/A2023-11-08

View Eversept Partners, LP's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Eversept Partners, LP's holdings